Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Abstract LB260: Potential prognostic/predictive biomarkers for sacituzumab govitecan in EVOKE-01

Marina Chiara Garassino, Peiwen Kuo, Niels Reinmuth, Nicolas Girard, Giannis Mountzios, Mariano Provencio, Yvonne Summers, Marcello Tiseo, Shan Tang, Riddhi Patel, Sabeen Mekan, Juliane M. Jürgensmeier

Cancer Res (2025) 85 (8_Supplement_2): LB260.

https://doi.org/10.1158/1538-7445.AM2025-LB260

Published: 25 April 2025

View articletitled, Abstract LB260: Potential prognostic/predictive biomarkers for sacituzumab govitecan in EVOKE-01

Journal Articles

Abstract CT250: Trofuse-023: A phase 3, randomized, open-label study of pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT) as first-line treatment for metastatic squamous non-small-cell lung cancer (NSCLC)

Marina Chiara Garassino, James Chih-Hsin Yang, Delvys Rodríguez-Abreu, Nikolaj Frost, Sung Yong Lee, Gilberto de Castro, Jr, Nir Peled, Ignacio Casarini, Dariusz Kowalski, Takayasu Kurata, Yoshitaka Zenke, Bin Zhao, Niyati Bhagwati, Zachary Zimmer, Caicun Zhou

Cancer Res (2025) 85 (8_Supplement_2): CT250.

https://doi.org/10.1158/1538-7445.AM2025-CT250

Published: 25 April 2025

View articletitled, Abstract CT250: Trofuse-023: A phase 3, randomized, open-label study of pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT) as first-line treatment for metastatic squamous non-small-cell lung cancer (NSCLC)

Journal Articles

Abstract 3565: Personalized Drug Discovery Process (PDDP): An AI-driven, sustainable, and equitable solution for cancer drug discovery

Pietro Veronesi, Adekunle Odunsi, Marciano Siniscalchi, Marina Chiara Garassino

Cancer Res (2025) 85 (8_Supplement_1): 3565.

https://doi.org/10.1158/1538-7445.AM2025-3565

Published: 21 April 2025

View articletitled, Abstract 3565: Personalized Drug Discovery Process (PDDP): An AI-driven, sustainable, and equitable solution for cancer drug discovery

Journal Articles

Abstract 1538: Impact of MCT1 inhibition on NSCLC metabolism and sensitivity to therapy

Robert Cameron, Massar Alsamraae, Maia G. Clare, Nia G. Hammond, Christine Bestvina, Marina Chiara Garassino, Brandon Faubert

Cancer Res (2025) 85 (8_Supplement_1): 1538.

https://doi.org/10.1158/1538-7445.AM2025-1538

Published: 21 April 2025

View articletitled, Abstract 1538: Impact of MCT1 inhibition on NSCLC metabolism and sensitivity to therapy

Journal Articles

Abstract 5506: Circulating immature neutrophils early detect hyperprogressive disease upon first-line PD-1/PD-L1 inhibitors in non-small cell lung cancer patients selecting best candidates for platinum-based chemotherapy and PD-1/PD-L1 inhibitors combinations

Cancer Res (2023) 83 (7_Supplement): 5506.

https://doi.org/10.1158/1538-7445.AM2023-5506

Published: 04 April 2023

View articletitled, Abstract 5506: Circulating immature neutrophils early detect hyperprogressive disease upon first-line PD-1/PD-L1 inhibitors in non-small cell lung cancer patients selecting best candidates for platinum-based chemotherapy and PD-1/PD-L1 inhibitors combinations

Journal Articles

Abstract 1669: Immunometabolism of circulating neutrophils in hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) alone or in combination with platinum-based chemotherapy (PCT) in non-small cell lung cancer (NSCLC) patients (pts)

Cancer Res (2021) 81 (13_Supplement): 1669.

https://doi.org/10.1158/1538-7445.AM2021-1669

Published: 01 July 2021

View articletitled, Abstract 1669: Immunometabolism of circulating neutrophils in hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) alone or in combination with platinum-based chemotherapy (PCT) in non-small cell lung cancer (NSCLC) patients (pts)

Journal Articles

Abstract 4480: Circulating and tumor associated neutrophil subtypes correlate with hyperprogressive disease (HPD) upon immunecheckpoint inhibitors (ICI) in advanced non-small cell lung cancer (aNSCLC) patients (pts) and in vivo models

Roberto Ferrara, Claudia Proto, Giuseppe Lo Russo, Diego Signorelli, Arsela Prelaj, Giulia Galli, Nicoletta Zilembo, Alessandro De Toma, Giuseppe Viscardi, Riccardo Lobefaro, Marta Brambilla, Monica Ganzinelli, Giuliano Molino, Giovanna Talarico, Marina Chiara Garassino, Mario Colombo, Sabina Sangaletti

Cancer Res (2020) 80 (16_Supplement): 4480.

https://doi.org/10.1158/1538-7445.AM2020-4480

Published: 15 August 2020

View articletitled, Abstract 4480: Circulating and tumor associated neutrophil subtypes correlate with hyperprogressive disease (HPD) upon immunecheckpoint inhibitors (ICI) in advanced non-small cell lung cancer (aNSCLC) patients (pts) and in vivo models

Journal Articles

Abstract CT402: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion): First results of a global collaboration to address the impact of COVID-19 in patients with thoracic malignancies

Marina Chiara Garassino

Cancer Res (2020) 80 (16_Supplement): CT402.

https://doi.org/10.1158/1538-7445.AM2020-CT402

Published: 15 August 2020

View articletitled, Abstract CT402: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion): First results of a global collaboration to address the impact of COVID-19 in patients with thoracic malignancies

Journal Articles

Abstract CT220: IMpower133: Updated OS and exploratory analyses of first-line (1L) atezolizumab (atezo) + carboplatin (C) + etoposide (E) in extensive-stage SCLC (ES-SCLC)

Cancer Res (2020) 80 (16_Supplement): CT220.

https://doi.org/10.1158/1538-7445.AM2020-CT220

Published: 15 August 2020

View articletitled, Abstract CT220: IMpower133: Updated OS and exploratory analyses of first-line (1L) atezolizumab (atezo) + carboplatin (C) + etoposide (E) in extensive-stage SCLC (ES-SCLC)

Journal Articles

Abstract 3385: Liquid biopsy to detect MET exon 14 skipping (METex14) and MET amplification in patients with advanced NSCLC: Biomarker analysis from VISION study

Xiuning Le, Dariusz Kowalski, Byoung Chul Cho, Pierfranco Conte, Enriqueta Felip, Marina Chiara Garassino, Santiago Viteri, Gee-Chen Chang, John Richart, Luiz Paz-Ares, Dilafruz Juraeva, Josef Straub, Christopher Stroh, Paul Paik

Cancer Res (2020) 80 (16_Supplement): 3385.

https://doi.org/10.1158/1538-7445.AM2020-3385

Published: 15 August 2020

View articletitled, Abstract 3385: Liquid biopsy to detect MET exon 14 skipping (METex14) and MET amplification in patients with advanced NSCLC: Biomarker analysis from VISION study

Journal Articles

Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity

Marina Chiara Garassino, Valter Torri, Mario Paolo Colombo, Antonio Sica

Cancer Res (2018) 78 (20): 5729–5730.

https://doi.org/10.1158/0008-5472.CAN-18-2245

Published: 15 October 2018

View articletitled, Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity

Journal Articles

Abstract 760: Detection of EGFR T790M mutation by ddPCR in untreated NSCLC patients: Correlation with clinical outcome

Monica Ganzinelli, Eliana Rulli, Elena Tamborini, Adele Busico, Giuseppe Lo Russo, Giulia Corrao, Milena Vitali, Marina Chiara Garassino, Massimo Broggini, Mirko Marabese

Cancer Res (2017) 77 (13_Supplement): 760.

https://doi.org/10.1158/1538-7445.AM2017-760

Published: 01 July 2017

View articletitled, Abstract 760: Detection of EGFR T790M mutation by ddPCR in untreated NSCLC patients: Correlation with clinical outcome

Journal Articles

Abstract 4406: Role of KRAS in modulating the metabolomic profile and the response of NSCLC cells to PI3K/mTOR and AMPK interfering agents

Elisa Caiola, Laura Brunelli, Mirko Marabese, Marina Chiara Garassino, Gabriella Farina, Massimo Broggini, Roberta Pastorelli

Cancer Res (2014) 74 (19_Supplement): 4406.

https://doi.org/10.1158/1538-7445.AM2014-4406

Published: 01 October 2014

View articletitled, Abstract 4406: Role of KRAS in modulating the metabolomic profile and the response of NSCLC cells to PI3K/mTOR and AMPK interfering agents

Update search

NARROW

Format

Journal

Article Type

Issue Section

Date

Availability

Abstract LB260: Potential prognostic/predictive biomarkers for sacituzumab govitecan in EVOKE-01

Abstract CT250: Trofuse-023: A phase 3, randomized, open-label study of pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT) as first-line treatment for metastatic squamous non-small-cell lung cancer (NSCLC)

Abstract 3565: Personalized Drug Discovery Process (PDDP): An AI-driven, sustainable, and equitable solution for cancer drug discovery

Abstract 1538: Impact of MCT1 inhibition on NSCLC metabolism and sensitivity to therapy

Abstract 5506: Circulating immature neutrophils early detect hyperprogressive disease upon first-line PD-1/PD-L1 inhibitors in non-small cell lung cancer patients selecting best candidates for platinum-based chemotherapy and PD-1/PD-L1 inhibitors combinations

Abstract 1669: Immunometabolism of circulating neutrophils in hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) alone or in combination with platinum-based chemotherapy (PCT) in non-small cell lung cancer (NSCLC) patients (pts)

Abstract 4480: Circulating and tumor associated neutrophil subtypes correlate with hyperprogressive disease (HPD) upon immunecheckpoint inhibitors (ICI) in advanced non-small cell lung cancer (aNSCLC) patients (pts) and in vivo models

Abstract CT402: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion): First results of a global collaboration to address the impact of COVID-19 in patients with thoracic malignancies

Abstract CT220: IMpower133: Updated OS and exploratory analyses of first-line (1L) atezolizumab (atezo) + carboplatin (C) + etoposide (E) in extensive-stage SCLC (ES-SCLC)

Abstract 3385: Liquid biopsy to detect MET exon 14 skipping (METex14) and MET amplification in patients with advanced NSCLC: Biomarker analysis from VISION study

Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity

Abstract 760: Detection of EGFR T790M mutation by ddPCR in untreated NSCLC patients: Correlation with clinical outcome

Abstract 4406: Role of KRAS in modulating the metabolomic profile and the response of NSCLC cells to PI3K/mTOR and AMPK interfering agents

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only